<DOC>
	<DOCNO>NCT00040651</DOCNO>
	<brief_summary>Scleroderma , systemic sclerosis ( SSc ) , diffuse connective tissue disease characterize change skin , blood vessel , skeletal muscle , internal organ . The purpose study determine safety value self bone marrow transplant chemotherapy patient severe SSc .</brief_summary>
	<brief_title>Safety Value Self Bone Marrow Transplants Following Chemotherapy Scleroderma Patients</brief_title>
	<detailed_description>SSc chronic disease involve abnormal growth connective tissue , support skin internal organ . This disease affect skin , make hard tight ; also damage blood vessel internal organ heart , lung , kidney . Initially , precursor blood cell mobilize bone marrow blood stream chemotherapy white blood cell growth factor administer . These precursor ( autologous stem cell ) harvest bloodstream procedure call leukapheresis ; precursor blood cell transplant back patient 's body high dose chemotherapy . Autologous stem cell prefer donor bone marrow risk rejection . This study evaluate safety effectiveness self bone marrow transplant intravenous chemotherapy patient SSc . Prior transplantation , patient undergo diphtheria/tetanus ( DT ) vaccination blood collection . Two week vaccination , patient Hickman catheter insert body admit hospital receive mobilization chemotherapy intravenous ( IV ) cyclophosphamide . Patients discharge receive cyclophosphamide therapy understanding must stay locally must return outpatient clinic daily blood sample draw receive injection growth factor , G-CSF , stimulate blood cell production . Patients undergo leukapheresis clinic white blood cell ( WBC ) count reach 2500 cells/mm3 . A machine call Nexell Isolex 300i use remove T-cells cell collect leukapheresis . After leukapheresis pre-transplant procedure complete , patient hospitalize approximately 14 21 day . On Days 1 5 hospitalization , patient receive IV fludarabine one several possible dose level cyclophosphamide . On Days 3 5 , patient receive IV thymoglobulin kill T-cells cause damage systemic sclerosis . On Day 8 , patient receive stem cell previous leukapheresis procedure . While hospital , patient monitor daily blood collection discharge white blood cell count return safe , stable level . Prior discharge hospital , patient undergo second leukapheresis . Patients require stay locally Pittsburgh 100 day post-transplantation . Study visit occur clinic every week first three month transplant 4 , 5 , 6 , 9 , 12 , 18 , 24 month post-transplantation . Study visit include physical exam blood collection ; patient also ask complete questionnaire . Patients undergo electrocardiogram ( EKG ) Month 1 , chest x-ray Month 6 , 24-hour urine collection Months 6 18 , pulmonary test Months 6 , 12 , 24 . Additional leukapheresis conduct 12 24 month post-transplant assess patient ' health .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>ECOG performance status 0 2 Willing participate portion protocol , include pharmacodynamic immunologic study patient care followup visit Willing stay Pittsburgh area 100 day posttransplantation Willing use acceptable method contraception HIV infect Hepatitis C virus infect Active infection Small malabsorption syndrome Immunosuppressive therapy steroid within 4 week study entry Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>Mesna</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>T-Cell</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Scleroderma</keyword>
</DOC>